Lapsed Jan 23, 2026 on the fee record · High confidence
20-year base term ends Sep 23, 2031
Second maintenance fee unpaid; grace period ended.
Held by GlaxoSmithKline LLC
Filed Sep 3, 2015 as application 14/844,051 · Granted Jan 23, 2018
Base term, 20 years from filing
Today
Lapsed Jan 23, 2026
2011
2031
Clock starts
Sep 23, 2011
Sep 23, 2011
No longer in force
Jan 23, 2026
Jan 23, 2026
Granted
Jan 23, 2018
Jan 23, 2018
Term would have run to
Sep 23, 2031
Sep 23, 2031
base term
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,435,988, to Sep 23, 2031. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Sep 23, 2031: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 23, 2011, when application PCT/US2011/052857, the earliest non-provisional in its chain, was filed (this one was filed Sep 3, 2015) | Sep 23, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,435,988) | resolves to Sep 23, 2031, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Jan 23, 2026 | High confidence |
| Computed term end | The steps above, in order | Jan 23, 2026 | High confidence |
This family
| Application PCT/US2011/052857 | PCT application no patent term | no patent term |
| Application 13/876,853 | Abandoned not computed | not computed |
| US 8,674,090 | Lapsed on the fee record Mar 2026 | Mar 2026 |
| US 8,865,912 | Lapsed on the fee record Oct 2026 | Oct 2026 |
| US 9,062,003 | In force Sep 2031 | Sep 2031 |
| US 9,156,797 | In force Sep 2031 | Sep 2031 |
| US 9,872,860 | this patent Jan 2026 | Jan 2026 |
| US 10,314,845 | In force Sep 2031 | Sep 2031 |
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 9, 2015 Reel 36517, frame 293 | Qu, Junya; Rivero, Ralph A.; Sanchez, Robert; Tedesco, Rosanna | GlaxoSmithKline LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,435,988, ends no earlier than this term, so it caps nothing.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.